IP Library Granted Patent US 8,258,128
Granted Patent B2
US 8,258,128 · App. 12/224,734 · Granted Sep 4, 2012

Organic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,258,128
App. No.
12/224,734
Granted
Sep 4, 2012
Kind
B2
Abstract

The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment of pain in animals and humans. More particularly, the present invention relates to pharmaceutical, preferably veterinary compositions and methods for reducing inflammation and pain associated with acute inflammation of body parts, particularly joints, due to injury or due to arthritic conditions or other disease conditions.

Claims (23)

1. A compound of the formula Ia

wherein R 3 is C 1 -C 6 -alkyl;

R 4 is OH, NH 2 , or C 1 -C 6 -alkyloxy;

R 5 is H, or halogen; and

R 6 is H, halogen, NO 2 , CN or C 1 -C 6 -alkyl;

or a physiologically acceptable ester or a pharmaceutical acceptable salt thereof.

2. A compound of formula Ia according to claim 1 , wherein R 3 is methyl or ethyl; and R 4 is OH, methoxy or ethoxy.

3. A compound according to claim 1 selected from the group consisting of [7-Chloro-10-hydroxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [7-Chloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [7-Chloro-10-ethoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2-Chloro-10-hydroxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2-Chloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2-Chloro-10-ethoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2-Chloro-7-fluoro-10-hydroxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; (2-Chloro-7-fluoro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2-Chloro-7-fluoro-10-ethoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2,7-Difluoro-10-hydroxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2,7-Difluoro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2,7-Difluoro-10-ethoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2,7-Dichloro-10-hydroxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; [2,7-Dichloro-10-ethoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid; and [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid or a physiologically acceptable ester or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 3 , wherein the compound is cis[2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid or a physiologically acceptable ester or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a physiologically acceptable adjuvant, diluent or carrier.

6. The pharmaceutical composition according to claim 5 , wherein said composition is an oral or transdermal dosage form.

7. The pharmaceutical composition according to claim 5 wherein said composition is a veterinary composition in a palatable dosage form.

8. A method of treating pain or discomfort of inflammatory ailments in a human or animal in need of such treatment, which method comprises administering to said subject an analgesically effective amount of a compound according to claim 1 .

9. A compound according to claim 3 , wherein the compound is [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-4-ylidene]-acetic acid.

10. A pharmaceutical composition comprising the compound of claim 9 and a physiologically acceptable adjuvant, diluent, or carrier.

11. A method of treating pain in a subject in need thereof, comprising administering the compound of claim 9 .

12. A process for preparing a compound of formula Ia according to claim 1 , wherein a compound of formula

wherein R 3 , R 5 and R 6 are defined as given for formula Ia, is reacted with a compound of formula

(MeO) 2 POCH 2 COOMe  IX,

optionally in the presence of a basic catalyst to form a compound of formula Ia.

13. The process of claim 12 , wherein said compound of formula Ia is a racemic ester, the process further comprising the step of saponifying said ester and isolating at least one isomer of said compound.

14. A compound of formula Ia according to claim 1 , wherein R 3 is C 1 -C 6 -alkyl, R 4 is OH, NH 2 or C 1 -C 6 -alkyloxy, R 5 is halogen, and R 6 is H or halogen, or a pharmaceutically acceptable salt thereof.

15. A compound of the formula I according to claim 14 , wherein R 3 is methyl or ethyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2015
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 034926/0670 →
CORRECTIVE ASSIGNMENT TO CORRECT THE LISTED ASSIGNEE NOVARATIS PHARMA GMBH, BRUNNER STRASSE 59 1230 VIENNA AUSTRIA (SHOULD BE REMOVED) PREVIOUSLY RECORDED ON REEL 021937 FRAME 0405. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 7, 2012
From: BOLLINGER, PIETRO; PRASHAD, MAHAVIR; RISS, BERNHARD; KING, JANET DAWSON; HIESTAND, PETER C.; LIU, YUGANG; KING, JONATHAN; SCHMID, VINCENT; SCHUERCH, FRIEDRICH
To: NOVARTIS AG
Reel/Frame 028771/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2008
From: BOLLINGER, PIETRO; PRASHAD, MAHAVIR; RISS, BERNHARD; KING, JANET DAWSON; HIESTAND, PETER C.; LIU, YUGANG; KING, JONATHAN; SCHMID, VINCENT; SCHUERCH, FRIEDRICH
To: NOVARTIS AG; NOVARTIS PHARMA GMBH
Reel/Frame 021937/0405 →